Cat. No. 4663
Chemical Name: 4'-Hydroxy-3'-methoxyacetophenone
Biological ActivityNADPH oxidase inhibitor. Demonstrates anti-inflammatory properties in a mouse model of carrageenan-induced pleurisy. Bioactivated by intracellular peroxidases; acts as an antioxidant in endothelial cells and vascular smooth muscle cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Impellizzeri et al (2011) Effect of apocynin, a NADPH oxidase inhibitor, on acute lung inflammation. Biochem.Pharmacol. 81 636. PMID: 21147071.
Heumüller et al (2008) Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51 211. PMID: 18086956.
Stolk et al (1994) Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am.J.Respir.Cell Mol.Biol. 11 95. PMID: 8018341.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Apocynin include:
Hassler et al (2014) Reactive oxygen species and lipid peroxidation inhibitors reduce mechanical sensitivity in a chronic neuropathic pain model of spinal cord injury in rats. Int J Mol Med 131 413. PMID: 25051888.
Walsh et al (2014) The role of Nox1 and Nox2 in GPVI-dependent platelet activation and thrombus formation. Redox Biol 2 178. PMID: 24494191.
Do you know of a great paper that uses Apocynin from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Apocynin, supplier, Apocynin, NADPH, oxidases, inhibitors, inhibits, leukocytes, anti-inflammatory, peroxidases, Tocris Bioscience, NADPH Oxidase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective myeloperoxidase (MPO) inhibitorINCB 024360-analog
Potent indoleamine 2,3-dioxygenase (IDO) inhibitor
April 1 - 5, 2017
Washington, D.C., USA